Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-28
2006-11-28
Mckenzie, Thomas (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S402000
Reexamination Certificate
active
07141601
ABSTRACT:
The present invention relates to a dendrite elongation inhibitor for melanocytes consisting of a compound represented by the following general formula (1):and/or a salt thereof,wherein R1, R2, and R3each independently represent a C1-4alkyl group or hydrogen atom,and a skin preparation for external use comprising the dendrite elongation inhibitor for melanocytes as an active ingredient.
REFERENCES:
patent: 2002/0065300 (2002-05-01), Seiberg et al.
patent: 08-133949 (1996-05-01), None
patent: 08-208451 (1996-08-01), None
patent: 10-287544 (1998-10-01), None
patent: 11-079968 (1999-03-01), None
patent: 2000-13718 (2000-04-01), None
patent: 2000-103718 (2000-04-01), None
patent: 2001335485 (2001-12-01), None
patent: 01/56580 (2001-09-01), None
Zhu et al., “Separation and determination of homoisoflavonoids in Ophiopogon japonicus by reversed-phase high-performance liquid chromatography”, Journal of Chromatography, vol. 437, pp. 265-267.
Kaneda et al., “Studies on the components of ophiopogon roots (China). I”, Yakugaku Zasshi, vol. 103, pp. 1133-1139.
Tada et al., Studies on the constituents of ophiopogonis tuber. V. Isolation of a novel class of homoisoflavonoids and determination of their structures (1), Chemical & pharmaceuticla Bulletin, vol. 28, pp. 1477-1484.
Huang et al., “Benzoquinones, a homoisoflavanone and other constituents from polygonatum alte-lobatum”, Phytochemistry, vol. 44, pp. 1369-1373.
Yoshiaki et al., “Comparative studies on the constituents of ophiopogonis tuber and its congeners. IV. studies on the homoisoflavonoids of the subterranean part of ophiopogon ohwii Okuyama and O.jaburan (Kunth) Lodd”, Chemical & Pharmaceutical Buletin, vol. 33, pp. 5358-5363.
Takatsuki et al., “Cytotoxic components of ophiopogonis tuber”, Natural Medicines, vol. 52, pp. 145-150.
Watanabe et al., “Comparative studies on the constituents of ophiopogonis tuber and its congeners (part V), studies on the constituents of the subterranean part of ophiopogon chekiangensis Kimura et H. Migo.”, Shoyakugaku Zasshi, vol. 44, pp. 117-121.
Zhu et al., “Isolation and identification of homoisoflavanor from Maidong”, Yaoxue Xue bao, vol. 22, pp. 679-684.
Watanabe, et al. “Comparative Studies on the Constituents of Ophiopogonis Tuber and Its Congeners IV. Studies on the Homoisoflavonoids of the Subterranean Part ofOphiopogon ohwiiIkuyama andO. jaburan(Kunth) Lodd,”Chem. Pharm. Bull., vol. 33, No. 12, pp. 5358-5363, 1985.
International Search Report issued to a related foreign application.
Kanamaru Akiko
Saeki Yuko
Tada Akihiro
Knobbe Martens Olson & Bear LLP
Mckenzie Thomas
Pola Chemiocal Industries Inc.
Rahmani Niloofar
LandOfFree
Dendrite elongation inhibitor for melanocyte and skin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dendrite elongation inhibitor for melanocyte and skin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dendrite elongation inhibitor for melanocyte and skin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3650220